Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 71NIH 4NETWORK 4INDUSTRY 3UNKNOWN 1OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Glioblastoma 40Carcinoma, Non-Small-Cell Lung 22Head and Neck Neoplasms 20Brain Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Glioma 11Lung Neoplasms 8Carcinoma, Squamous Cell 8Breast Neoplasms 8Astrocytoma 8Rectal Neoplasms 7Neoplasms 7Prostatic Neoplasms 6Mucositis 5Esophageal Neoplasms 5Carcinoma 4Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Colorectal Neoplasms 3Xerostomia 2Stomatitis 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neoplasms, Squamous Cell 2Lymphoma 2Leukemia 2Laryngeal Diseases 2Gliosarcoma 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2

Interventions

Paclitaxel 18pembrolizumab 16Cisplatin 16Fluorouracil 15Irinotecan 13tislelizumab 9Oxaliplatin 8Nivolumab 8Docetaxel 8Leucovorin 6Capecitabine 5spartalizumab 4Levoleucovorin 4Carboplatin 4lenvatinib 3durvalumab 3Radiotherapy 3Drug Therapy 3toripalimab 2sintilimab 2regorafenib 2elgemtumab 2atezolizumab 2Itraconazole 2Injections 2Gemcitabine 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tremelimumab 1sitravatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Squamous Cell Carcinoma × Radiotherapy × Clear all
NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03957590 2026-04-13

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

BeOne Medicines

Phase 3 Completed
370 enrolled 17 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT00573131 2022-06-22

Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

Boston Scientific Corporation

Phase 2 Terminated
137 enrolled 9 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡